TIMP2 and cancer: In clinical studies for cancer treatments, use of MMP inhibitors has been associated with musculoskeletal side effects (Nemunaitis et al., 1998; Wojtowicz-Praga et al., 1998; Rosemurgy et al., 1999; Tierney et al., 1999; King et al., 2003; Peterson, 2006; Fingleton, 2008), so the ability of Ala-TIMP2 to provide beneficial effects without acting on MMPs may make it a more viable approach.